

Lung Cancer

## A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

**Trial Status**  
Completed

**Trial Runs In**  
6 Countries

**Trial Identifier**  
NCT03092739 MO29978

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with any stage of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).

**Hoffmann-La Roche**  
Sponsor

**N/A**  
Phase

---

**NCT03092739 MO29978**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
All

**Healthy Volunteers**  
No

---